IP Library Granted Patent US 11,859,023
Granted Patent B2
US 11,859,023 · App. 17/370,920 · Granted Jan 2, 2024

Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof

Inventors: Jeffrey Arnold (Andover, MA); David A. Ralph (Columbus, OH)
Assignee: Navidea Biopharmaceuticals, Inc.
C08B37/0021A61K51/065
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,859,023
App. No.
17/370,920
Granted
Jan 2, 2024
Kind
B2
Abstract

Disclosed herein is method for conjugating a metal chelating agent to a functionalized dextran by reacting a chelator with an aminated dextran backbone, where the chelator comprises a one, and only one, derivatized carboxylic acid group to form a chelator-dextran complex. In certain aspects, the dextran-chelator complex is substantially free of intra- or intermolecular crosslinking. In certain aspects, the functionalized dextran is an amine dextran, an alkynyl dextran, or a thiol dextran. In exemplary implementations, the functionalized dextran is an amine dextran. In further embodiments, one and only one carboxylic acid group on the chelating agent is derivatized as a N-hydroxysuccinimide (NHS) ester.

Claims (24)

1. A method for conjugating a metal chelating agent to a functionalized dextran comprising:

reacting a chelator with an aminated dextran backbone, wherein the chelator comprises a plurality of carboxylic acid groups, wherein only one carboxylic acid group is activated to form a chelator-dextran complex, and wherein the additional carboxylic acid group(s) are each conjugated to a protecting group;

wherein the dextran-chelator complex is substantially free of intra- or intermolecular crosslinking.

2. The method of claim 1 , wherein the functionalized dextran is an amine dextran, an alkynyl dextran, or a thiol dextran.

3. The method of claim 2 , wherein the functionalized dextran is an amine dextran.

4. The method of claim 3 , wherein the one and only one carboxylic acid group on the chelating agent is derivatized as a N-hydroxysuccinimide (NHS) ester.

5. The method of claim 1 , wherein the chelator is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).

6. The method of claim 1 , wherein only the one carboxylic acid group is available for activation after the additional carboxylic acid group(s) are each conjugated to a protecting group.

7. The method of claim 1 , further comprising removing the protecting groups conjugated to the additional carboxylic acid group(s) from the chelator-dextran complex.

8. The method of claim 1 , wherein the protecting groups are chosen from a list consisting of t-butyl esters, benzyl esters, phenyl esters, allyl esters, silyl esters, methyl esters, ortho esters, and oxazolines.

9. The method of claim 8 , wherein the protecting groups are t-butyl groups.

10. The method of claim 1 , wherein the chelator is diethylenetriaminepentaacetic acid (DTPA).

11. The method of claim 1 , wherein prior to reacting the chelator with the aminated dextran backbone, the chelator is synthesized by conjugating the additional carboxylic acid group(s) to the protecting groups, resulting in the only one carboxylic acid group being active to form a mono-NHS-chelator.

12. The method of claim 11 , wherein each of the protecting groups is removed, prior to reaction with the dextran backbone.

13. The method of claim 12 , wherein the chelator is DTPA.

14. The method of claim 13 , wherein the protecting groups are chosen from a list consisting of: t-butyl esters, benzyl esters, phenyl esters, allyl esters, silyl esters, methyl esters, ortho esters, and oxazolines.

15. The method of claim 14 , wherein the protecting groups are t-butyl groups.

16. A method for synthesizing an amine dextran comprising:

a. reacting a chelator with an aminated dextran backbone, wherein the chelator comprises a plurality of carboxylic acid groups, each conjugated to a protecting group with the exception of only one carboxylic acid derivatized as a single activated mono-N-hydroxysuccinimide (NHS) ester, to form a chelator-dextran complex;

b. removing the protecting groups from each of the plurality of carboxylic acid groups; and

c. adding a plurality of mannose moieties to the chelator dextran complex through amidate linkage to the dextran backbone.

17. The method of claim 16 , wherein the chelator is DTPA or DOTA.

18. The method of claim 17 , wherein the protecting groups are chosen from a list consisting of: t-butyl esters, benzyl esters, phenyl esters, allyl esters, silyl esters, methyl esters, ortho esters, and oxazolines.

19. The method of claim 18 , wherein the protecting groups are t-butyl groups.

Assignments (4)
US BANKRUPTCY COURT SALE ORDER DATED JAN. 30, 2026 TO RELEASE SECURITY INTEREST RECORDED AT 069165 / 0332 Recorded Feb 12, 2026
From: SCOTT, JOHN KIM, JR.
To: NAVIDEA BIOPHARMACEUTICALS, INC.
Reel/Frame 074831/0644 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY INFORMATION PREVIOUSLY RECORDED ON REEL 68711 FRAME 393. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Sep 27, 2024
From: NAVIDEA BIOPHARMACEUTICALS, INC.
To: SCOTT, JOHN KIM, JR.
Reel/Frame 069165/0332 →
SECURITY INTEREST Recorded Sep 26, 2024
From: NAVIDEA BIOPHARMACEUTICALS, INC.
To: NAVIDEA BIOPHARMACEUTICALS, INC.
Reel/Frame 068711/0393 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2023
From: ARNOLD, JEFFREY; RALPH, DAVID A.
To: NAVIDEA BIOPHARMACEUTICALS, INC.
Reel/Frame 062291/0257 →
Continuity (2)
Provisional Application 63049485 · Jul 8, 2020
Related Publication 20220010036A1 · Jan 13, 2022